image: Relative expression of SOX9, Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition markers in hypospadias foreskin tissues. (A) The protein expressions of SOX9, Wnt3a, β-catenin, LEF1, GSK3β, NF-κB were measured by Western blotting. (B) Detection of SOX9, Wnt3a, β-catenin, TCF1, c-Myc, cyclin D1 mRNA levels (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). (C) Immunofluorescence showed that the expression of SOX9 in Hypospadias foreskin group was significantly lower than that in Normal foreskin group(fluorescence microscope × 200). (D) Western blotting analyses of α-SMA, Vimentin, E-cadherin, Occludin and β-catenin protein levels of tissue specimens. (E) Detection of α-SMA, Vimentin, E-cadherin, Occludin and β-catenin mRNA levels (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Credit: Pediatric Discovery
A recent study has uncovered the pivotal role of the transcription factor SOX9 in the development of hypospadias, a common congenital condition that affects male children. The research highlights how SOX9 regulates critical molecular pathways involved in urethral development, including the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition (EMT). The study reveals that reduced SOX9 expression leads to impaired EMT and abnormal Wnt signaling in tissues affected by hypospadias. These findings provide new insights into the condition's molecular underpinnings, potentially paving the way for innovative, targeted therapies.
Hypospadias is a widespread congenital disorder, characterized by an abnormal placement of the urethral opening, impacting as many as 3.42% of male children worldwide. Beyond the physical consequences, this condition can lead to psychological and fertility issues. Surgical repair remains the only current treatment, but complications are common, and the genetic and cellular mechanisms involved remain poorly understood. With the prevalence of hypospadias on the rise, coupled with the challenges of surgical treatment, a deeper understanding of its molecular causes is urgently needed.
Published (DOI: 10.1002/pdi3.94) on May 14, 2024, in Pediatric Discovery, the study conducted by researchers from the Children’s Hospital of Chongqing Medical University delves into the role of SOX9 in the development of hypospadias. The study investigates the expression of SOX9 in foreskin tissues from hypospadias patients, focusing on its influence on the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition (EMT).
The research team analyzed foreskin samples from 15 children with hypospadias, comparing them with normal foreskin tissues from children undergoing circumcision. Using molecular techniques such as transcription-polymerase chain reaction (RT-PCR), Western blotting, and immunofluorescence, the researchers found that SOX9 expression was notably downregulated in hypospadias tissues. This downregulation was linked to reduced expression of key components of the Wnt/β-catenin pathway, including Wnt3a, LEF1, and GSK3β. Additionally, mesenchymal markers like Vimentin and α-SMA were also diminished, while epithelial markers such as E-cadherin, Occludin, and ZO-1 were elevated, suggesting a disrupted EMT process. Inhibition of SOX9 in foreskin fibroblasts replicated these effects, further confirming SOX9’s crucial role in regulating Wnt/β-catenin signaling and EMT during urethral development.
Dr. Xing Liu, the lead researcher, stressed the significance of the findings: "This is the first study to pinpoint SOX9 as a key player in hypospadias development. By understanding how SOX9 governs Wnt/β-catenin signaling and EMT, we can identify potential new therapeutic strategies to treat this condition."
The implications of these findings extend beyond basic science, with significant potential for clinical application. By elucidating the molecular mechanisms of hypospadias, the study uncovers new therapeutic targets that could lead to non-surgical treatments. Additionally, these insights into the genetic basis of the condition could improve surgical outcomes, offering better predictions and tailored approaches. The research also opens up new possibilities for early diagnosis and intervention, which could help mitigate the psychological and fertility-related challenges faced by affected individuals.
###
References
DOI
Original Source URL
https://doi.org/10.1002/pdi3.94
Funding information
This work was financed by the National Natural Science Foundation of China (81970571), Natural Science Foundation Project of Science and Technology Commission of Chongqing (2022NSCQ-MSX0328) and Chongqing Medical University Program for Youth Innovation in Future Medicine.
About Pediatric Discovery
Pediatric Discovery is a Gold Open Access publication and officially sponsored by The National Clinical Research Center for Child Health and Disorders of China, and Children’s Hospital of Chongqing Medical University. The journal does not charge any submission fees. The Article Publication Charge (APC) is currently waived for accepted manuscripts. Pediatric Discovery is an open access and peer-reviewed international journal. The journal aims to advance the health and well-being of infants, children, and adolescents by disseminating cutting-edge discovery and knowledge in the field. It provides a platform for publishing and discussing the most important and state-of-the-art basic, translational and clinical discoveries affecting child and adolescent health and disorders in all aspects of pediatric medicine. Directory of Open Access Journals (DOAJ).
Journal
Pediatric Discovery
DOI
Subject of Research
Not applicable
Article Title
SOX9 regulates epithelial-mesenchymal transformation by mediating the Wnt/β-catenin signaling pathway in hypospadias
Article Publication Date
14-May-2024
COI Statement
The authors declare that they have no competing interests.